Crown raises $28.8M for oncology work

Santa Clara, CA-based Crown Biosciences has raised $28.8 million in a third round of venture financing, according to Xconomy. The cancer drug developer says it plans to use the funding to expand services in integrated cancer drug discovery and translational oncology, as well as to fund new initiatives in other therapeutic areas. OrbiMed Advisors Caduceus Asia Partners Fund, Argonaut Private Equity, the CID Group, IBT and CDIB Capital Investment led the round. Crown release | Report

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.